Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin PK in critically ill patients on ECMO
NCT06329518Phase 1Withdrawn
- Sponsor
- Hartford Hospital
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 1, open-label trial of rezafungin in sepsis, sponsored by Hartford Hospital. Primary endpoint: Clearance at 168 hours. Planned start Jul 2024; status: withdrawn.
02
Drugs
rezafungin
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06329518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329518.